OLANZAPINE tablet, orally disintegrating

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

olanzapine (UNII: N7U69T4SZR) (olanzapine - UNII:N7U69T4SZR)

Available from:

Dr.Reddy's Laboratories Limited

INN (International Name):

olanzapine

Composition:

olanzapine 5 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Oral olanzapine is indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [ see Clinical Studies (14.1)].    When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks  when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see  Warnings and Precautions (5.5 )].  Oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. Efficacy was established in three clinical trials in adult patients with manic or mixed episodes

Product summary:

Olanzapine orally disintegrating tablets USP, 5 mg are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, debossed with R-262 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30                                                                  NDC 55111-262-30 Carton of 10 packs (NDC 55111-262-78), each pack containing 10 tablets (NDC 55111-262-79) Carton of 30 packs (NDC 55111-262-31), each pack containing 1 tablet (NDC 55111-262-11) Carton of 3 packs (NDC 55111-262-81), each pack containing 10 tablets (NDC 55111-262-79) Olanzapine orally disintegrating tablets 10 mg USP, are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, debossed with R-263 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30                                                                   NDC 55111-263-30 Carton of 10 packs (NDC 55111-263-78), each pack containing 10 tablets (NDC 55111-263-79) Carton of 30 packs (NDC 55111-263-31), each pack containing 1 tablet (NDC 55111-263-11) Carton of 3 packs (NDC 55111-263-81), each pack containing 10 tablets (NDC 55111-263-79) Olanzapine orally disintegrating tablets USP, 15 mg are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, debossed with R-264 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30                                                                   NDC 55111-264-30 Carton of 10 packs (NDC 55111-264-78), each pack containing 10 tablets (NDC 55111-264-79) Carton of 30 packs (NDC 55111-264-31), each pack containing 1 tablet (NDC 55111-264-11) Carton of 3 packs (NDC 55111-264-81), each pack containing 10 tablets (NDC 55111-264-79) Olanzapine orally disintegrating tablets USP, 20 mg are yellow-colored, capsule-shaped tablets, flat on one side and concave on the other side, debossed with R-265 on the flat side and plain on the concave side and are supplied in bottles of 30, carton of 10 packs containing 10 tablets each, carton of 30 packs containing 1 tablet each and carton of 3 packs containing 10 tablets each. Bottles of 30                                                                   NDC 55111-265-30 Carton of 10 packs (NDC 55111-265-78), each pack containing 10 tablets (NDC 55111-265-79) Carton of 30 packs (NDC 55111-265-31), each pack containing 1 tablet (NDC 55111-265-11) Carton of 3 packs (NDC 55111-265-81), each pack containing 10 tablets (NDC 55111-265-79) Store olanzapine orally disintegrating tablets, USP at controlled room temperature, 20° to 25°C (68° to 77°F) [see USP]. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses.  Protect olanzapine orally disintegrating tablets, USP from light and moisture.

Authorization status:

Abbreviated New Drug Application

Patient Information leaflet

OLANZAPINE- OLANZAPINE TABLET, ORALLY DISINTEGRATING
Dr.Reddy's Laboratories Limited
----------
Medication Guide
Olanzapine Orally Disintegrating Tablets USP
(oh lan' za peen)
Read the Medication Guide that comes with olanzapine orally
disintegrating tablets before you start taking
them and each time you get a refill. There may be new information.
This Medication Guide does not take the
place of talking to your doctor about your medical condition or
treatment. Talk with your doctor or
pharmacist if there is something you do not understand or you want to
learn more about olanzapine orally
disintegrating tablets.
What is the most important information I should know about olanzapine
orally disintegrating tablets?
Olanzapine orally disintegrating tablets may cause serious side
effects, including:
1. Increased risk of death in elderly people who are confused, have
memory loss and have lost touch with
reality (dementia-related psychosis).
2. High blood sugar (hyperglycemia).
3. High fat levels in your blood (increased cholesterol and
triglycerides), especially in teenagers age 13 to 17,
or when used in combination with fluoxetine in children age 10 to 17.
4. Weight gain, especially in teenagers age 13 to 17, or when used in
combination with fluoxetine in children
age 10 to 17.
These serious side effects are described below.
1. Increased risk of death in elderly people who are confused, have
memory loss and have lost touch with
reality (dementia-related psychosis). Olanzapine orally disintegrating
tablets are not approved for treating
psychosis in elderly people with dementia.
2. High blood sugar (hyperglycemia). High blood sugar can happen if
you have diabetes already or if you
have never had diabetes. High blood sugar could lead to:
•
a build up of acid in your blood due to ketones (ketoacidosis)
•
coma
•
death
Your doctor should do tests to check your blood sugar before you start
taking olanzapine orally disintegrating
tablets and during treatment. In people who do not have diabetes,
sometimes high blood sugar

Summary of Product characteristics

OLANZAPINE- OLANZAPINE TABLET, ORALLY DISINTEGRATING
DR.REDDY'S LABORATORIES LIMITED
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
OLANZAPINE ORALLY
DISINTEGRATING TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
OLANZAPINE ORALLY DISINTEGRATING TABLETS.
OLANZAPINE ORALLY DISINTEGRATING TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1996
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
• ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH
ANTIPSYCHOTIC DRUGS
ARE AT AN INCREASED RISK OF DEATH. OLANZAPINE IS NOT APPROVED FOR THE
TREATMENT OF
PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS (5.1, 8.5, 17)
WHEN USING OLANZAPINE AND FLUOXETINE IN COMBINATION, ALSO REFER TO THE
BOXED WARNING
SECTION OF THE PACKAGE INSERT FOR SYMBYAX.
RECENT MAJOR CHANGES
Warnings and Precautions, Tardive Dyskinesia (5.6) 10/2019
Warnings and Precautions, Use in Patients with Concomitant Illness
(5.14) Removed 4/2020
Warnings and Precautions, Anticholinergic (antimuscarinic) Effects
(5.14) 4/2020
INDICATIONS AND USAGE
Olanzapine is an atypical antipsychotic indicated:
_As oral formulation for the:_
• Treatment of schizophrenia. (1.1)
Adults: Efficacy was established in three clinical trials in patients
with schizophrenia: two 6-week trials
and one maintenance trial. (14.1)
Adolescents (ages 13 to 17): Efficacy was established in one 6week
trial in patients with schizophrenia
(14.1). The increased potential (in adolescents compared with adults)
for weight gain and dyslipidemia
may lead clinicians to consider prescribing other drugs first in
adolescents. (1.1)
• Acute treatment of manic or mixed episodes associated with bipolar
I disorder and maintenance
treatment of bipolar I disorder. (1.2)
Adults: Efficacy was established in three clinical trials in patients
with manic or mixed episodes of bipolar
I disorder: two 3- to 4-week trials and one maintenance trial. (14.2)
Adolescents (ages 13 to 17): Efficacy was established in one 3-